Supplementary Figure S1 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
DOI:
10.1158/2326-6066.26422445.v1
Publication Date:
2024-08-01T07:37:37Z
AUTHORS (9)
ABSTRACT
<p>Selection of mCLN-617 component parts</p>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....